Endoleaks graft extension or coil embolization
Download
1 / 35

Endoleaks : graft extension or coil embolization ? - PowerPoint PPT Presentation


  • 235 Views
  • Uploaded on

Endoleaks : graft extension or coil embolization ?. Claudio Schönholz,MD Associate Professor of Radiology Heart and Vascular Center Medical University of South Carolina Charleston, SC. CANNES 2004. Endoleak. “Presence of flow at the aneurysmal sac after stent-graft treatment”.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Endoleaks : graft extension or coil embolization ?' - kalkin


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Endoleaks graft extension or coil embolization
Endoleaks : graft extensionor coil embolization ?

Claudio Schönholz,MDAssociate Professor of RadiologyHeart and Vascular Center Medical University of South CarolinaCharleston, SC

CANNES 2004


Endoleak

Endoleak

“Presence of flow at the aneurysmal sac after stent-graft treatment”

White GH, May J, Waugh RC, Chaufour X, Yu W.

Type III and type IV endoleak: toward a complete definition of blood flow in the sac

after endoluminal AAA repair. J Endovasc Surg 1998;5:305309.


Endoleak Types

  • Type I endoleak

    • Proximal or distal attachment

  • Type II endoleak

    • Retrograde branch flow

  • Type III endoleak

    • Structural defect or component junction

  • Type IV endoleak

    • Trans-graft leakage or porosity


Prevention of type i endoleak
Prevention of Type I Endoleak

  • Case Selection

  • 20 % oversizing of the endograft.

  • Generous overlapping of segments.

  • Graft covers the aorta and common iliac arteries from the renal arteries down to the iliac artery bifurcation.


Possible reasons of having low incidence of type i endoleaks
Possible reasons of having low incidence of Type I endoleaks:

  • No procedure was considered finished until complete sealing of the endograft was obtained.

  • Sealing of the ends and connections was achieved by applying balloon dilatation, cuffs and malleable stents at the ends ( Extra-large Palmaz)

PARODI, JC







When should type ii endoleaks be treated
WHEN SHOULD TYPE II ENDOLEAKS BE TREATED?

“If the endoleak continues to be present on the 6-month scan, there is a small chance that it will spontaneously thrombose”

  • Treat a type II endoleak if there is evidence of sac enlargement

  • Intervene if a type II endoleak is present on the 6-month scan regardless of the status of an aneurysm sac

6-month CT scan


Endoleak anatomy
ENDOLEAK ANATOMY

  • Simple: small cavity and has ingress and egress from a single vessel

  • Complex: multiple ingress and egress vessels


Endoleak anatomy simple

Blood enters during systole into the endoleak cavity, swirling around, leaving the endoleak cavity during diastole

Physiology similar to

a pseudo-aneurysm

May spontaneously thrombose prior to the 6-month CT scan

ENDOLEAK ANATOMY“Simple”


Endoleak anatomy complex
ENDOLEAK ANATOMY swirling around, leaving the endoleak cavity during diastole“Complex”

  • Multiple ingress and egress vessels

  • Behave like arteriovenous malformations

  • Persists longer than 6 months.


How to treat Type II Endoleaks: swirling around, leaving the endoleak cavity during diastoleEmbolize the artery feeding the endoleak cavity by a transarterial route ?

  • This technique has proved ineffective, providing only short-term response if the sac can not be reached by the embolic agent.

  • Endoleaks will recur by recruiting additional aortic branch vessels.


The endoleak cavity acts as an “Arteriovenous malformation nidus,” and thrombosing this nidus is what provides a successful and durable response.

Richard A. Baum, MD

Do stable type II endoleaks require treatment after EVAR

Endovascular Today


Type ii endoleak embolization with glue
Type II Endoleak: nidus,” and thrombosing this nidus is what provides a successful and durable response. Embolization with Glue


Type ii endoleak from ima

TYPE II ENDOLEAK FROM IMA nidus,” and thrombosing this nidus is what provides a successful and durable response.

67 Years old High Risk Patient.

6.5 cm AAA treated 14 month ago with Gore Excluder Device.

CT scan showed Type II Endoleak from IMA and the AAA remain same size.

Indication:Endovascular Embolization


How to treat type ii endoleaks translumbar needle stick
How to treat Type II Endoleaks: nidus,” and thrombosing this nidus is what provides a successful and durable response. translumbar needle stick ?

  • Coils and glue to completely thrombose the endoleak cavity

  • Instead of treating feeding vessels, the endoleaks themselves are being embolized

  • The connection between ingress and egress vessels, as well as the endoleak cavity, is destroyed


Type ii endoleak
Type II Endoleak nidus,” and thrombosing this nidus is what provides a successful and durable response.


Translumbar embolization
Translumbar Embolization nidus,” and thrombosing this nidus is what provides a successful and durable response.

Translumbar

Gelfoam-Thrombin

6 Months FU


Translumbar Embolization of Type 2 Endoleaks after Endovascular Repair of Abdominal Aortic Aneurysms

  • 7 Patients with Type 2 Endoleak

  • 4 lumbar, 3 IMA

  • 19-gauge,20cm needle w/5fr.Teflon Sheath

  • Gianturco Coils (CooK)

  • 100% Initial Success

  • No Complications

R.A.Baum;C.Cope; R.Fairaman;J.CarpenterJ.Vasc Interv Radiol 2001;12:111-116


Type iii endoleak
Type III Endoleak Endovascular Repair of Abdominal Aortic Aneurysms


Type III Endoleak Endovascular Repair of Abdominal Aortic Aneurysms


Type iii endoleak1
Type III Endoleak Endovascular Repair of Abdominal Aortic Aneurysms


Management of endoleaks
Management of Endoleaks Endovascular Repair of Abdominal Aortic Aneurysms

  • Type I: Immediate treatment. Balloon,Cuff, Palmaz or Conversion to Open Procedure.

  • Sealed Type I: If large Treat ,If small Watch. If size does not decrease Treat.

  • Type II: Treat after 6 months if aneurysmal size do not decrease.

  • Late Type I or III: Treat immediately.


Obliteration of the aneurysmal sac in abdominal aortic aneurysms in an animal model

Obliteration of the Aneurysmal Sac in Abdominal Aortic Aneurysms in an Animal Model

Renan Uflacker,MD


Pig #3 Aneurysms in an Animal Model

AAA creation

Volume measurement

15 cc’s

Post Treatment

Endoleak


24 Week FU Aneurysms in an Animal Model

Pig # 3


Results
Results Aneurysms in an Animal Model

  • The treatment of the AAA was technically successful in all animals with total exclusion of the sac

  • The AAA sac acquired a firm rubberish consistency after treatment

  • Fibrosis and calcifications were detected within the sac, mostly around the graft and in contact with the aortic wall after 4 to 6 weeks.

  • There was inflammatory reaction to the Dacron material and to the polymer (to a lesser extent)

  • Significant adhesion of the AAA with surrounding structures was observed


Results1
Results Aneurysms in an Animal Model

  • After 4 to 6 weeks there is a tendency for shrinkage of the AAA sac, apparently maximized by the 24th week

  • There was no sac recanalization in the follow up time ranging from 1 to 24 weeks

  • The controls at 6 and 12 weeks showed shrinkage of the AAA sac (histology not ready yet)


Conclusions
Conclusions Aneurysms in an Animal Model

  • pGlcNAc Glucosamine in the gel form is an unique hemostatic material

  • Promotes rapid clotting within the AAA sac

  • Also effective under systemic anticoagulation

  • Effective aneurysm sac filling with occlusion of branches

    as necessary

  • Easy to use and cost effective

  • It seems to have gradual longer term absorption allowing AAA shrinkage over a period of 24 weeks but not before 6 weeks

  • Experience is necessary for volumetric measurement

  • A human trial is warranted


ad